OSTEOARTHRITIS
Intraarticular stem cell injection favoured over oral acetaminophen after 6-mo in knee OA treatment
Int J Rheum Dis. 2018 Jan;21(1):140-147. doi: 10.1111/1756-185X.1313961 patients with Kellgren-Lawrence grade II-III knee osteoarthritis were randomized to treatment with either a single intraarticular injection of bone morrow-derived mesenchymal stem cells (BM-MSC) or oral acetaminophen 500mg every 8 hours for 6 months. Patients were assessed for outcome on a visual analog scale for pain and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Patients were assessed 1 week, 1 month and 6 month follow-up. Results demonstrated significantly favourable results in the BM-MSC group compared to the acetaminophen group for VAS pain and the WOMAC Pain and Stiffness subscales at 1 weeks, 1 month, and 6 months, and for the WOMAC Physical function subscale at 1 month and 6 months.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
